Wednesday, January 27, 2016 10:33:10 AM
$CGIX: What’s Holding It Back?
Posted on January 27, 2016 | By Dr Kanak Kanti De | Leave a response
This paragraph from a subscriber: Continued positive CGIX developments with their comprehensive Immuno-Oncology Testing Portfolio; their Nov $4 secondary offering hurt us longs but with positive 3Q earnings and 2015 headlines (below), I remain steadfastly long. Basics: 26M cap, 52 wk hi/lo $12.75/$1.90. 2015 highlights: ICON partnership; Response Genetics acquisition (included 3 patents); third patent awarded for FHACT test; $1M net cash from NOL tax credit transfer, Frigate Ventures 6.5% stake; SWK Holdings 6.9% stake; signed as in-network provider with Harvard Pilgrim Healthcare (HPHC) and Blue Cross (BCBS) bringing total lives covered to 50M; CLL trial contract; Moffitt research collaboration.) The consensus sales forecast for 2016 sales is more than $36 million, which means that the stock is trading at less than 1x sales. I believe it will surpass its current $7 target. The real question we longs continuously ask is when?
https://drkkd.com/3312/cgix-whats-holding-it-back/
______________________________________________-
CGIX
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM